Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age

Am J Cardiol. 2003 Nov 1;92(9):1083-6. doi: 10.1016/j.amjcard.2003.07.007.

Abstract

Of 1,369 consecutive patients who underwent stent-assisted coronary angioplasty and who were treated with glycoprotein IIb/IIIa inhibitors during these procedures, 17.5% were >or=75 years of age. Compared with patients <75 years old, those >or=75 years of age had similar procedural and in-hospital outcomes but significantly higher rates of hemorrhagic stroke (0.08% vs 1.2%, p <0.001).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Blood Vessel Prosthesis Implantation / adverse effects
  • Cerebral Hemorrhage / etiology
  • Cerebral Hemorrhage / prevention & control*
  • Humans
  • Middle Aged
  • Outcome Assessment, Health Care
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use*
  • Retrospective Studies
  • Risk
  • Stents / adverse effects
  • Stroke / etiology
  • Stroke / prevention & control*

Substances

  • Platelet Glycoprotein GPIIb-IIIa Complex